Stefano Rodino - Publications

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.

Journal: American journal of therapeutics

Published: July 23, 2026

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.

Journal: American journal of therapeutics

Published: July 23, 2026

Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study.

Journal: Advances in therapy

Published: February 11, 2026

Evaluation of the Effect of a Cranberry Formulation in Reducing the Inflammatory State and Improving the Management of Symptoms in Patients with Symptomatic Uncomplicated Diverticular Disease: A Prospective, Open-Label, Single-Arm, Multi-Center, Pilot Study.

Journal: Pharmaceutics

Published: November 13, 2025

Empagliflozin might improve chronic inflammatory bowel diseases also in humans.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: September 30, 2025

Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.

Journal: Journal of clinical medicine

Published: August 27, 2025

Artificial Intelligence Control Methodologies for Shape Memory Alloy Actuators: A Systematic Review and Performance Analysis.

Journal: Micromachines

Published: May 20, 2025

Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study.

Journal: Intestinal research

Published: April 29, 2025

Real‑world safety and efficacy of biological agents in inflammatory bowel disease: a one-year post-marketing pharmacovigilance observational study in the Calabria region.

Journal: Pharmacological reports : PR

Published: April 11, 2025

Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE study.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: March 08, 2025

Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study.

Journal: Journal of clinical medicine

Published: September 23, 2024

Bowel movement alterations predict the severity of diverticular disease and the risk of acute diverticulitis: a prospective, international study.

Journal: Intestinal research

Published: March 22, 2024